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Abstract
Objectives At a European Society of Neuroradiology (ESNR) Annual Meeting 2015 workshop, commonalities in practice,
current controversies and technical hurdles in glioma MRI were discussed. We aimed to formulate guidance on MRI of glioma
and determine its feasibility, by seeking information on glioma imaging practices from the European Neuroradiology community.
Methods Invitations to a structured survey were emailed to ESNR members (n=1,662) and associates (n=6,400), European
national radiologists’ societies and distributed via social media.
Results Responses were received from 220 institutions (59% academic). Conventional imaging protocols generally include T2w,
T2-FLAIR, DWI, and pre- and post-contrast T1w. PerfusionMRI is used widely (85.5%), while spectroscopy seems reserved for
specific indications. Reasons for omitting advanced imaging modalities include lack of facility/software, time constraints and no
requests. Early postoperative MRI is routinely carried out by 74% within 24–72 h, but only 17% report a percent measure of
resection. For follow-up, most sites (60%) issue qualitative reports, while 27% report an assessment according to the RANO
criteria. A minority of sites use a reporting template (23%).
Conclusion Clinical best practice recommendations for glioma imaging assessment are proposed and the current role of advanced
MRI modalities in routine use is addressed.
Key Points
• We recommend the EORTC-NBTS protocol as the clinical standard glioma protocol.
• Perfusion MRI is recommended for diagnosis and follow-up of glioma.
• Use of advanced imaging could be promoted with increased education activities.
• Most response assessment is currently performed qualitatively.
• Reporting templates are not widely used, and could facilitate standardisation.
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Introduction
Gliomas are a diverse group of neoplasms, the principal
treatment for which is surgical resection followed by ra-
diation and/or chemotherapy. Despite ongoing efforts to
advance treatments, practically all adult gliomas eventual-
ly progress and have an overall poor prognosis [1].
Magnetic resonance imaging (MRI) is fundamental to
the characterisation of brain tumours, guides the surgical
strategy and is required to monitor treatment response.
There is a current lack of MRI protocol standardisation
[2], which can be problematic for patient management.
Differences in scanning protocols (spatial and contrast
resolution, image planes, sequences, etc.), whether within
the same institution or between institutions, may affect
image interpretation, assessment of contrast enhancement
and (volume) changes in follow-up examinations [3]. For
advanced imaging modalities, the absence of uniform pro-
tocols may delay their implementation, hamper the estab-
lishment of threshold values, and in the worst case render
the technique non-diagnostic.
In 2015, the Diagnostic Committee of the European
Society of Neuroradiology (ESNR) held a workshop on
glioma imaging practices at its 38th Annual Meeting in
Naples, Italy. Among the audience present, the lack of
recommendations for MRI in clinical practice was found
to be a universal deficit, whilst variations in protocols
seemed to exist.
Best practice is defined as the conscientious and judi-
cious use of current best evidence in making decisions
about the care of individual patients [4]. The published
evidence around brain tumour MRI protocols constitutes
a complex and dynamic entity, particularly where ad-
vanced techniques are concerned. Key changes have oc-
curred in the understanding of glioma, which are
reflected in the recent World Health Organisation
(WHO) classification [5]. It is now clear that the biolog-
ical aggressiveness of glioma subtypes is primarily influ-
enced by their molecular genetic composition, in some
cases discrepant from histological results and conven-
tional imaging features [6–8]. MRI protocols must ac-
count for the new integrated approach to glioma classifi-
cation, and should aim to complement and add value in
the diagnostic workup. The goal is to develop imaging
protocols, which reflect best practice, but also to consid-
er differences between institutions in equipment, levels
of expertise, and financial factors in resource-limited
healthcare systems. Furthermore, protocol harmonisation
could serve as a means of quality assurance and support
multicentre research into new treatments.
Consensus recommendations have recently been devel-
oped for glioma imaging in clinical trials. The United
States National Brain Tumor Society (NBTS), Society
fo r Neuro -onco logy (SNO) and the Eu ropean
Organisation for Research and Treatment of Cancer
(EORTC) jointly published the EORTC-NBTS protocol
[9]. The main aim of this protocol is to enable in a defined
group of patients a reproducible assessment of tumour
volume change according to the response assessment in
neuro-oncology (RANO) criteria [10]. The focus of this
protocol is therefore on anatomical T1-weighted (T1w),
T2-weighted (T2w) and T2w fluid-attenuated inversion
recovery (T2-FLAIR) sequences, and also includes rec-
ommendations for diffusion-weighted imaging (DWI).
The question has been raised whether the EORTC-
NBTS protocol would be suitable for implementation in
a clinical setting. A simple adoption of a trial protocol
into the challenging clinical service may, however, be
problematic. In the clinical context, a variable number
of questions need to be addressed such as diagnosis, dif-
ferential diagnosis as well as treatment planning, out-
come and monitoring. Furthermore, a clinical protocol
must be time efficient and applicable in a wide range
of medical institutions, and must affect the management
of the individual patient. Advanced techniques, which are
not relevant in current clinical trials and therefore not
included in the EORTC-NBTS protocol, can be important
for patient management.
This paper aims to provide best clinical practice recom-
mendations on conventional and advanced MRI of glioma
patients and assesses whether the EORTC-NBTS protocol
would be suitable for routine clinical practice. To inform the
recommendations and to assess their feasibility, information
was sought from European institutions about MRI practices,
technical parameters and common diagnostic challenges. To
this end, a structured survey was carried out to ensure the
involvement and representation of the European neuroradiol-
ogy community in the guidance.
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European survey on glioma MRI practices
Method
An online questionnaire was designed using a Google forms
open access toolbox (Google.com,Mountainview, CA, USA).
The questionnaire featured 87 items, divided into multiple
choice, single best choice and free text questions on personal
practice, preferred MRI techniques and clinical scenarios (see
online Supplement 1). The questionnaire was optimised and
tested by peers such that it would take a maximum of 10 min
to fill out. This information was given at the start of the
questionnaire.
Questions were derived from issues raised at the 38th
ESNR annual meeting workshop on brain tumour imaging
(attendance ± 150 people), as well as those identified during
the development of the EORTC-NBTS protocol. Survey invi-
tations were emailed to all ESNR members (n=1,662), non-
members who had expressed their interest in ESNR-activities
in the past (n=6,400), European national neuroradiological
societies (The Netherlands, Belgium and the UK), and distrib-
uted via LinkedIn and Twitter. The survey was open for 1
month, from 1March to 1 April 2016, with one reminder sent.
To avoid duplicate bias, participants were instructed to supply
institution details or confirm they were the only person an-
swering from their centre.
Results
Demographic and institution data (online Supplement 2,
Table 1)
Two hundred and twenty-seven professionals working in 31
out of 51 European countries completed the survey; seven
were duplicates from the same institution, resulting in re-
sponses from 220 institutions. A proportion of questionnaires
(8.2 %) included in the analysis were submitted by individuals
currently working outside Europe. Figure 1 provides an over-
view of the responses by country.
A number of questions included the option ‘other’. If this
was answered by < 5 % of individuals, percentages are not
quoted in the results. A few undecipherable free text answers
were excluded from the analysis.
Primary diagnosis and follow up (online Supplement 2,
Table 2)
Typical glioma standard MRI protocols lasted between 20–60
min. The proportion of institutions per country that use proto-
cols shorter than 30 min is displayed in Fig. 2.
In more than 95 %, the protocols included T2w, T2-
FLAIR, pre- and post-contrast T1w, and DWI. At many insti-
tutions (65 %) T2*w or susceptibility weighted imaging
(SWI) were part of the MRI protocol. 3D anatomical se-
quences were used by most (81.8 %) of the institutions, most
commonly post-contrast T1w. In free text answers, reasons
given for not using 3D imaging included time pressure
(n=10), quality concerns, scanner limitations, financial rea-
sons and lack of technical support (n=2 each). Most (77.7
%) institutions used the same protocol for glioma follow-up
as for primary diagnosis. Some chose a different protocol for
follow up with omission or selective use of sequences, most
frequently MR spectroscopy (MRS) or perfusion MRI
(pMRI).
Contrast-enhanced MRI (online Supplement 2, Table 3)
To depict enhancement, the most commonly (72.3 %) per-
formed sequence was FSPGR/MPRAGE. Not all users felt
comfortable using this 3D gradient echo sequence as the sole
sequence to assess contrast uptake. In free text answers, the
most frequently (n=48) reported concern was absent or sub-
optimal sensitivity to detect enhancement, followed by arte-
fact, reduced sensitivity, and a risk of missing small lesions.
Diffusion-weighted imaging (DWI; online Supplement 2,
Table 4)
DWI was almost always (99.1 %) performed in glioma imag-
ing. ADC was much more often (78.2 %) assessed by visual
comparison with normal appearing brain than quantitatively.
Nearly all users employed b values of 0 and 1,000 s/mm2, with
some acquiring an additional b-value of 500 s/mm2.
Perfusion MRI (pMRI; online Supplement 2, Table 5)
Most institutions (85 %) applied pMRI (most frequently dy-
namic susceptibility contrast [DSC; 81.8 %]) for initial grad-
ing and/or glioma follow-up. The use of this modality was
homogeneously distributed across Europe. Some institutions
(21.4 %) reported use of either DSC plus one other perfusion
technique, and rarely all three were acquired. Free text an-
swers highlighted usefulness of pMRI in differentiating che-
moradiation effects from tumour progression (n=55) and for
grading (n=36).
MR Spectroscopy (MRS; online Supplement 2, Table 6)
The majority (80.4 %) of institutions used MRS in clinical
brain tumour imaging, but rarely as part of the routine proto-
col. The largest group (35.2 %) of users acquired MRS occa-
sionally, upon request or for a specific indication. Free text
answers regarding MRS indications featured lesion character-
isation (n= 56), including distinction of tumour from non-
neoplastic conditions, and grading (n=21). Less commonly
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MRS was employed for brain tumours in general or to differ-
entiate therapy effects from tumour recurrence.
Functional MRI (fMRI; online Supplement 2, Table 7)
Approximately half (49.8 %) of participating institutions used
fMRI in clinical practice, mostly for surgical planning (95.4
%). Free text answers on the clinical impact reported its value
for operative planning, to guide the interventional approach,
and to determine tumour resectability. Functions assessed
were language lateralisation and localisation, visual cortex
localisation and motor cortex localisation (resting state fMRI
not assessed). fMRI scan times varied substantially lasting up
to 1 h, depending on tasks.
Diffusion-tensor imaging (DTI) tractography (online
Supplement 2, Table 8)
Nearly two-thirds (63.7 %) of participating institutions carried
out DTI tractography in their practice, generally for
presurgical evaluation (88.2 %). Numerous free text answers
stated that DTI tractography was useful for operative
planning, underscoring the potential of DTI results to change
the surgical approach. Some users reported limited impact or
experience. The number of acquired directions varied signifi-
cantly, but over half (58.5 %) of the DTI performing institu-
tions acquired at least 20 directions in their clinical practice.
Clinical scenarios and issues
Early postoperative MRI (online Supplement 2, Table 9)At the
majority (74.3 %) of institutions, early postoperativeMRI was
routinely performed to assess the extent of glioma resection,
but few (17.2 %) radiologists provided a percent measure on
completeness of resection in their report, with no uniform
method identifiable from the free text answers (n=28).
Monitoring of therapy response (online Supplement 2,
Table 9) For glioma follow-up, most respondents (60.6 %)
undertook a qualitative assessment, and a smaller group
(27.1 %) obtained measurements according to the RANO
criteria [10]. Less than a quarter (23.3 %) of institutions incor-
porated a reporting template in their current practice.
Fig. 1 Institutional responses (%) per country. Countries with no responses are shaded grey
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Post-processing and non-use of advanced imaging (online
Supplement 2, Table 10) For all advanced modalities, data
post-processing was most commonly carried out by a radiol-
ogist. Multiple reasons featured amongst non-use of advanced
imaging, with lack of MRI equipment (40.5–49.5 %) slightly
dominating for all methods.
Discussion
A conventional MRI protocol consisting of T2w, T2-FLAIR,
DWI and pre- and post-contrast T1w appears representative of
standard glioma imaging practice in Europe. To the best of our
knowledge, level I evidence in the form of randomised con-
trolled trials for the MRI assessment of glioma is currently
lacking. Conventional MRI, but also the use of DWI and
pMRI for glioma characterisation are supported by some level
II evidence, and by numerous level III studies [11]. The cur-
rent data on the use of MRS, SWI, fMRI and DTI are restrict-
ed to level III evidence, mostly in the form of retrospective
comparative studies.
3D versus 2D imaging
3D (volumetric) imaging has clear advantages over 2D imag-
ing. First, reconstructions can be made in all planes, allowing
not only for a better appreciation of anatomical location, but
also for more accurate longitudinal assessment [12]. Second,
tumour volumes can be more accurately measured, in partic-
ular when this is done automatically [13]. In addition, the
higher through-plane resolution of 3D imaging reduces the
risk of missing small foci of contrast enhancement due to
partial volume effects [14]. FSPGR/MPRAGE appears overall
diagnostic for glioma imaging [15] and remains the most
widely available T1w 3D technique at present [9]. However,
some concerns exist regarding its suitability to depict post
contrast enhancement, increased susceptibility to movement
or pulsation artifacts, and lack of sensitivity for the detection
of leptomeningeal disease. The short repetition times used for
FSPGR/MPRAGE sequences are known to result in less
marked T1-dependent signal enhancement compared with
spin-echo using the same Gadolinium-chelate dose [16].
This effect was not found to be detrimental for small brain
Fig. 2 Percentage of MRI protocols of < 30 min duration for each
country. The remaining protocols nearly always lasted between 31 and
60 min. Amongst all 220 responses, only 2.7 % of glioma MRI protocols
were longer than 60 min
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lesions in vivo [17], but potentially superior 3D spin-echo
alternatives such as SPACE and CUBE [14, 18] could well
supersede FSPGR over time.
Diffusion-weighted imaging
DWI with a maximum b value of 1,000 s/mm2 matches the
EORTC-NBTS protocol and National Cancer Institute (NCI) -
International Society for Magnetic Resonance in Medicine
(ISMRM) consensus recommendations [19], which specify
the preferred use of 3 b-values (0, 500 and 1,000 s/mm2),
but acknowledge the fact that not all scanners have this capa-
bility. DWI can non-invasively contribute to estimating tu-
mour cellularity and grade [11, 20–22] and support the assess-
ment of therapy response, although as a single modality its
accuracy appears limited for the distinction of tumour and
radiation effects [23, 24]. Advanced diffusion techniques
could provide greater information on tissue microstructure
for the distinction of glioma molecular subgroups [25, 26,
83] and to support early response assessment, e.g. via para-
metric mapping [27–29], but such methods are not yet a clin-
ical standard.
T2*w and SWI
Susceptibility sensitive sequences may identify haemorrhage
or calcification in glioma primary diagnosis, and help depict
biopsy tracts. For SWI, an association has been observed be-
tween intratumoral susceptibility signals (ITSS), histological
WHO grade and relative cerebral blood volume (rCBV) [30].
The latter could provide substitute evidence of neovascularity,
where pMRI is unavailable. However, current evidence is
confined to a limited number of studies [31]. It remains doubt-
ful what information SWI can offer above other MRI se-
quences in glioma, with a possible exception of tumour mar-
gin delineation on contrast-enhanced SWI [32].
Perfusion MRI (pMRI)
DSC pMRI constitutes the primarily used perfusion method
(>80%) in the European institutions surveyed, which matches
published data [33], with nearly half of all users acquiring it
for all glioma indications. With DSC, high-grade glioma can
be differentiated from low-grade glioma using rCBV values
with high (95 %) sensitivity, but specificity is relatively low
(70 %) [34, 35]. This finding can be attributed to the misclas-
sification of low-grade gliomas with elevated rCBV, most no-
tably oligodendroglioma [36, 37]. Raised rCBV has recently
been highlighted as a characteristic of isocitrate dehydroge-
nase (IDH) wildtype glioma, even at a histological low grade
[38]. Furthermore, rCBV is the most validated perfusion pa-
rameter for the distinction of therapy effects from tumour pro-
gression [39, 40]. DSC studies consistently demonstrate that
rCBV is low in areas o f r ad ia t ion nec ros i s o r
pseudoprogression and high in tumour progression, allowing
for accurate (generally accuracy >90 %) distinction between
these entities [41–44].
Alternative perfusion techniques such as dynamic contrast-
enhanced (DCE) perfusion MRI and arterial spin labelling
(ASL), though less established, appear beneficial, especially
for such gliomas in which susceptibility effects render DSC
non-diagnostic. Neither technique has, however, been exten-
sively validated or integrated into clinical glioma imaging
practice to date.
Spectroscopy (MRS)
Whilst a high number of institutions have experience with
MRS in glioma, the survey results suggest that this method
is clinically used for specific indications only. The relative
intensity of metabolite spectra is influenced by echo time
(TE), with short or intermediate TE (30–144 ms) considered
preferable for glioma imaging. The benefit of MRS in the
distinction of glioma from non-neoplastic conditions was
highlighted inmany free text answers, which is well supported
by published data [45, 46]. The evidence for the selective use
of MRS in the distinction of glioma from other tumours, such
as metastases and brain lymphoma, remains indeterminate
[47, 48]. A potential advantage of MRS lies in the character-
isation of grade II oligodendroglioma, which commonly show
elevated rCBV, and may be misclassified as high-grade tu-
mour [49]. Otherwise, MRS finds a less prominent application
in grading, tumour classification, biopsy planning and charac-
terisation of radiation effects, with a moderate performance
shown for the latter indications in research [50–52]. For glio-
ma grading, Cho/Cr and Cho/NAA ratios have most frequent-
ly been reported to increase diagnostic accuracy, but in isola-
tion MRS remains inferior to rCBV measurements [47, 53].
For various thresholds, quantitative MRS suffers from a mis-
match between sensitivity and specificity, therefore a clear
diagnostic benefit in grading has only been shown through
combination with other techniques [34, 50, 53]. For the dif-
ferentiation of radiation necrosis and recurrent glioma, a sys-
tematic meta-analysis revealed a limited performance for
MRS, and strongly recommended its use only in combination
with other modalities [51].
fMRI and DTI tractography
With a principal clinical application of surgical planning, these
modalities are used to determine language lateralisation and
localisation of the motor and visual cortex as well as various
white matter tracts. Even though there is now substantial lit-
erature support for the use of task-based fMRI in glioma in the
pre-operative context, reported accuracies for this modality
are variable and its impact on clinical practice remains to be
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further established [54, 55]. Whilst the notion that DTI may
change the surgical approach is supported by data [56, 57] and
by the survey results, there are still important limitations to the
standardisation and clinical integration of tractography for
neurosurgical decision-making [58]. DTI was the only ad-
vanced imaging method for which users specifically men-
tioned limited experience, which is judged to reflect its partial
clinical establishment in Europe. Although it has been
highlighted that the reliability of DTI may increase according
to the number of diffusion directions acquired [57], no con-
sensus was identifiable from the survey results on an optimal
number of directions for clinical glioma imaging.
Non-use of advanced imaging
The fact that data processing for all advanced techniques
was most commonly carried out by a radiologist suggests
that these methods can be user-led. Such an arrangement
could however impact neuroradiology workflow. Lack of
MRI facility/equipment or software appears to be a great-
er limiting factor than time pressure. In some countries,
advanced techniques are not reimbursed, which can be a
significant hurdle. Lack of experience with and not know-
ing how to implement the techniques appear to be impor-
tant obstacles, especially for fMRI.
Reporting practices and quantification
With improved outcomes after complete or near-complete gli-
oma removal, postoperative residual measurement can be ex-
pected to become a focus of attention [59, 60]. Yet most radi-
ologists do not offer any quantitative information in their re-
port, and the literature provides no established system to as-
sess extent of resection.
In follow up, most respondents relied on a visual estimate
of tumour size despite existing RANO guidance. The current
RANO criteria incorporate two-dimensional measurements,
reflecting evidence indicating that changes in tumour volume
correlate with changes in unidimensional or two-dimensional
measurements [61–63], especially in high-grade glioma [64,
65]. The debate about whether volumetric glioma measure-
ments would be more accurate than linear measurements
and/or would impact clinical management is ongoing, espe-
cially for the response assessment of lower grade gliomas,
which may be challenged by subtle growth. Conflicting re-
sults exist regarding the reliability of low-grade glioma seg-
mentations [66, 67]. An additional hurdle is that currently
available semi-automated volumetric segmentation algo-
rithms tend to require manual editing [67–70].
An important issue revealed by the survey is the limit-
ed use of quantification methods for physiological param-
eters such as ADC and rCBV. Lack of available software
tools and/or familiarity with how to use them, as well as
time pressure may be contributing factors to the limited
quantification of findings [22, 71].
Survey limitations
From all persons contacted, only a small proportion (14 % of
ESNR members) responded, meaning the survey results may
not represent the entire neuroradiology community, almost
certainly introducing a response bias from those with a partic-
ular interest or expertise in glioma imaging. Moreover, it is
likely that the length of the survey contributed to the low
participation rate. Duplicate bias was avoided through only
allowing one person answer from each institution. The disad-
vantage of this approach is that variations in practice within
one department may not have been captured. This survey does
not cover most of the practices in outpatient general radiology
outside neuroradiology. We did not survey imaging practices
specific to paediatric glioma. However, a central imaging re-
view has been instituted for more than 20 years for paediatric
brain tumour studies and recommendations on imaging and
response assessment do exist [72, 73].
Best clinical practice recommendations
The following recommendations for MRI of glioma were
formulated taking together the information provided by a
peer group (>150 persons) discussion at the 38th ESNR
Annual Meeting in 2015, a structured survey of clinical
practices at over 200 European hospital institutions from
31 European countries, and the currently available litera-
ture on the subject (Fig. 3).
Conventional MRI protocol recommendations
The MRI sequences prescribed by the EORTC-NBTS proto-
col are widely used and scan durations generally allow for the
implementation of the 25–30 min EORTC-NBTS basic pro-
tocol in routine clinical practice. It is therefore recommended
that this should be used as a minimum clinical standard. As a
base structure this wil l support gl ioma imaging
standardisation across Europe with a view to establishing da-
tabases, which could be shared for radiomics and
radiogenomic analyses and upon which advanced techniques
can further build in the future.
3D imaging is preferable for the aforementioned rea-
sons and to support the transition into volumetric tumour
measurements, but it is recognised that further develop-
ment is required in this area. Where 3D T1w imaging is
adopted, this should be performed as isotropic sequences
before and after contrast, taking care to ensure consistent
and sufficient post contrast timing [9]. FSPGR/MPRAGE
remains the most widely available T1w 3D technique as
part of the standard MRI vendor Alzheimer’s Disease
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Neuroimaging Initiative (ADNI) protocol [74] and is rec-
ommended for clinical brain tumour trials [9]. Its use is
again endorsed here as an accessible method for serial
glioma imaging in clinical practice, but it could be re-
placed by 3D spin-echo T1w imaging where this is avail-
able, or supplemented with 2D spin-echo sequences
where optimisation of the 3D technique fails to be maxi-
mally sensitive to contrast enhancement. In individual cir-
cumstances where only 2D imaging achieves good quality
imaging within a clinically justifiable time, this may be
retained as a standard.
For diffusion analysis, quantitative ADC comparison to
normal brain is recommended, due to the potential pitfall of
visual assessment that a tumour surrounded by oedema will
appear dark on the ADCmap, even in the absence of diffusion
restriction. Because of the limited number of studies on T2*w/
SWI, these sequences are considered optional. We would sug-
gest using the same anatomical protocol for both primary di-
agnosis and follow-up to maximise comparability.
Advanced imaging recommendations
Perfusion MRI should be performed in gliomas of suspected
low grade that have not undergone histological evaluation or
prior to biopsy [34, 35, 39, 75]. The use of perfusion for serial
lesion assessment is recommended to identify malignant
transformation and to distinguish therapy effects
(pseudoprogression or radiation necrosis) from tumour pro-
gression [41–44]. A caveat must bemade that threshold values
are not simply transferable between institutions, as they very
much depend on scan parameters and post-processing methods
[76]. Based on currently available data, we recommended DSC
as the standard technique. Using pMRI routinely in all glioma
patients has several advantages: diagnostic information is avail-
able when needed, there is consistency of imaging protocols,
and both radiographers and radiologists gain and sustain expe-
rience with the technique. The available evidence strongly sup-
ports the use of a preload bolus technique, to overcome errors in
estimation cerebral blood volume due to contrast leakage ef-
fects [40, 77, 78]. Gadolinium contrast dose can – at 3.0T – be
kept low by splitting a single dose into preload and bolus injec-
tion, as outlined by the American Society of Functional
Neuroradiology (ASFNR) in 2015 [40]. The acquisition of an
appropriate baseline prior to contrast injection, high temporal
resolution (TR<1,500 ms), and fast contrast bolus injection
(preferably with a power injector) are important aspects of ap-
propriate DSC acquisition [79]. Consistency of acquisition and
post-processing techniques is critical, as differences between
software packages, and even algorithm alterations within the
same product may produce significantly different quantitative
perfusion results [78].Where sufficient evidence has been gath-
ered within an institution to show the reliability of an alternative
technique (DCE, ASL), this could be performed optionally,
preferably as an adjunct.
On the basis of the survey results and current data, MRS is
recommended in glioma as an optional modality for specific
indications as aforementioned. Its clinical indication should be
considered on an individual case basis, whereby caution is
advised regarding the use of MRS in isolation for some of
its less certain indications.
Fig. 3 Three possible options for
a glioma imaging protocol in
clinical practice based on the
EORTC-NBTS protocol (a), with
the addition of DSC perfusion
imaging (b, c). Option C has the
advantage over option B that it
has double the contrast dose for
post-contrast T1w imaging.
Option B may be preferred if non-
contrast enhanced T2-FLAIR is
desired. Please see Ellingson et al.
[9] for further considerations and
vendor-specific sequence details
on structural and diffusion-
weighted imaging. The moment
of contrast administration is
indicated in bold
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Because of their limited availability and limited use by the
survey respondents at the present time, fMRI and DTI will not
form part of these recommendations. The authors would like
to highlight their potential value, however, and would support
their use where adequate facilities, expertise and quality as-
surance measures exist. Further research into these techniques
is desirable and recommended.
Discussion of recommendations
Relatively easy adaptation towards the standard best clinical
practice recommendations can be expected, although some
variations throughout Europe are likely to remain, depending
on reimbursement strategies, practical and logistical setups
and availability of scanning facilities.
For advanced techniques, lack of facility, software and ex-
perience is likely to hamper their introduction at some institu-
tions, and it is possible that this could be especially the case for
centres from which no survey results were available. The neu-
roradiological community has an important role here to in-
clude such technical aspects in their various training
programmes.
For anatomical MRI, the use of measurements, bidirection-
al as a standard (and optionally volumetric, where segmenta-
tion software is available) is strongly recommended, as this
has been shown to increase diagnostic accuracy in serial fol-
low up [80]. The use of RANO criteria in clinical practice
could be facilitated by the introduction of structured reports,
which could also have other advantages both in terms of ac-
curacy and effectiveness [81, 82]. These are preferably devel-
oped together with treating physicians, to ensure that all rele-
vant information is consistently reported.
Regarding advanced imaging, we would like to emphasise
that, where possible, quantification is a powerful tool in clin-
ical practice, since it allows for the formulation of threshold or
reference values and avoids certain pitfalls of subjectivity.
Validation is, however, required. Multicentre research will
be of key importance to establish transferable quantification
methods for advanced imaging, which would be applicable
across scanners and vendor platforms.
Conclusion
The MRI sequences prescribed by the EORTC-NBTS proto-
col are well established in glioma imaging practice throughout
Europe, and we recommend that this protocol is adopted as the
clinical standard for anatomical MRI. Advanced imaging
methods may offer crucial diagnostic information, and should
be utilised where possible, within the constraints of currently
available data and local expertise. The results from the litera-
ture review and survey highlight the value of pMRI in glioma,
and also potentially important roles for other methods. The
relative lack of quantitative assessment and reporting tem-
plates reflects a further need for standardisation. The
harmonisation of glioma imaging protocols across Europe to-
gether with ongoing research should aim to support the devel-
opment of quantitative biomarkers for brain tumour diagnosis
and therapy response assessment.
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